Nanodrug-loaded Bifidobacterium bifidum conjugated with anti-death receptor antibody for tumor-targeted photodynamic and sonodynamic synergistic therapy. (1st July 2022)

• Record Type: Journal Article
• Authors: Li, Wenhao; Zhang, Zefei; Liu, Jie; Wang, Bo; Pu, Guangjin; Li, Ji; Huang, Yuqiao; Chu, Maoquan
• Is Part Of: Acta biomaterialia. Volume 146(2022)
• Page Start: 341
• Page End: 356
• Publication Date: 2022-07-01
• Subjects: B. bifidum -- Anti-death receptor antibody -- Tumor targeting -- Photodynamic and sonodynamic effects -- Synergistic therapy; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2022.05.016
• Languages: English
• ISSNs: 1742-7061

Abstract

Abstract: Using bacteria for tumor-targeted therapy has attracted much attention in recent years. However, how to improve the targeted delivery and cancer therapy efficacy is an important but challenging scientific issue. Herein, a drug delivery system using a probiotic as a carrier was developed for tumor-targeted photodynamic and sonodynamic synergistic therapy. In this system, chlorin e6 (Ce6) nanoparticles (NPs) were prepared and incorporated into B. bifidum, followed by the conjugation of anti-death receptor 5 antibody (anti-DR5 Ab). Interestingly, B. bifidum under 671 nm laser or ultrasound (US) irradiation could generate reactive oxygen species (ROS), and Ce6– B. bifidum –anti-DR5 Ab obtained could target hypoxic regions in tumor with high efficiency after intravenous injection. The ROS level generated by Ce6– B. bifidum –anti-DR5 Ab under both laser and US irradiation was much higher than the combined ROS generated separately using a laser and US for the same probiotics. The cytotoxicity and laryngeal tumor growth-inhibiting efficiency of Ce6– B. bifidum –anti-DR5 Ab under both laser and US irradiation were significant higher than the values obtained using laser or US irradiation alone, which demonstrated the synergistic effect on tumor growth. B. bifidum could be eliminated from the body without exerting harmful effects on mouse health. This strategy is a platform that can be extended to treat other solid tumors. Statement of significance: Using bacteria as drug delivery carriers will show unique advantages. However, how to improve the targeted delivery efficiency and tumor inhibiting capacity is a challenging scientific issue. Herein, a delivery system using a probiotic as carrier was developed for tumor-targeted therapy. In this delivery system, chlorin e6 nanoparticles were prepared and then incorporated into living Bifidobacterium bifidum ( B.bifidum ), followed by the conjugation of anti-death receptor 5 antibody. This delivery system could efficiently target to mouse tumors, accumulate the hypoxic areas and inhibit the tumor growth through the photodynamic and sonodynamic synergistic effect. Our results will provide a platform for B.bifidum –mediated tumor targeted therapy. Graphical abstract: Image, graphical abstract